Compare PTGX & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | CRL |
|---|---|---|
| Founded | 2006 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.8B |
| IPO Year | 2016 | 1999 |
| Metric | PTGX | CRL |
|---|---|---|
| Price | $143.78 | $273.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $108.23 | ★ $198.27 |
| AVG Volume (30 Days) | 456.7K | ★ 768.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | N/A | ★ $1,857,601,000.00 |
| Revenue This Year | $874.25 | N/A |
| Revenue Next Year | N/A | $3.04 |
| P/E Ratio | $63.06 | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $57.90 | $144.26 |
| 52 Week High | $160.81 | $303.31 |
| Indicator | PTGX | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 47.29 |
| Support Level | $141.95 | $215.89 |
| Resistance Level | $160.81 | $303.31 |
| Average True Range (ATR) | 5.37 | 7.37 |
| MACD | -0.89 | -4.37 |
| Stochastic Oscillator | 36.38 | 16.21 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.